Fucose-Binding Lectins for Respiratory Cancer Stem Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are ineffective in isolating and characterizing cancer stem cells (CSCs) due to their small population size and lack of specific markers, leading to late diagnosis and high recurrence rates in lung and other respiratory organ cancers.
Innovation Solution
Utilizing lectins that recognize the fucose α 1-2 galactose group, particularly the fucose α 1-2 galactose β 1-4 N-acetylglucosamine group, to label and isolate cancer stem cells from biological samples, enabling early detection and characterization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to detect and isolate cancer stem cells, then the detection process can be performed with standard techniques, but the methods fail to provide specific discrimination of cancer stem cells from other tumor cells due to lack of specific markers
Solution Approach 1:
The invention changes the detection parameter from generic tumor markers to specific carbohydrate structure markers (fucose α1-2 galactose groups) that are uniquely expressed on cancer stem cells. This parameter change enables specific discrimination of cancer stem cells from other tumor cells using lectins that recognize these unique carbohydrate structures.
Solution Approach 2:
The invention introduces lectins as intermediary molecules that specifically bind to fucose α1-2 galactose groups on cancer stem cell surfaces. These lectins act as mediators between the detection system and cancer stem cells, enabling specific identification and isolation without requiring direct genetic or protein-based markers.
2Quantity of substance
If the small population size of cancer stem cells (3-4% of tumor population) is considered, then the detection challenge increases, but conventional methods cannot effectively isolate this small population due to lack of specific markers
Solution Approach 1:
The invention shifts from detecting generic tumor cell properties to detecting specific carbohydrate structures (fucose α1-2 galactose groups) that are universally present on the surface of cancer stem cells regardless of their small population size. This parameter change enables effective detection and isolation of the rare cell population.
Solution Approach 2:
The invention employs lectins that can be conjugated with fluorescent or colored labels, enabling visual detection and flow cytometric sorting of cancer stem cells. This color/fluorescence change approach allows for precise identification and isolation of the small cancer stem cell population from the larger tumor cell population.
3Loss of time
If early diagnosis of cancer stem cells is implemented, then predictive factors for disease progression and recurrence can be identified, but the lack of specific markers currently prevents reliable early detection
Solution Approach 1:
The invention enables preliminary identification of cancer stem cells through detection of fucose α1-2 galactose groups, which are expressed early in tumor development. This preliminary action allows for early diagnosis and risk stratification before tumors become aggressive or metastatic, providing clinicians with predictive information for treatment planning.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early identification of cancer stem cells, providing a predictive factor for disease progression and allowing for tailored treatment strategies to reduce recurrence and aggressiveness.
Implementation Method 1
Utilizing lectins that recognize the fucose α 1-2 galactose group, particularly the fucose α 1-2 galactose β 1-4 N-acetylglucosamine group, to label and isolate cancer stem cells from biological samples
Data Source
AI summary
Disclosed is the in vitro use of at least one lectin which recognises the fucose alpha(1-2) galactose unit for labelling cancer stem cells of organs involved in respiration, in order to obtain labelled cancer stem cells of organs involved in respiration, in a biological sample. In one particular embodiment, the at least one lectin is chosen from the lectins Ulex Europaeus agglutinin 1 (UEA-1) or the homologue thereof, Trichosanthes japonica agglutinin II (TJA-II), Agaricus Bisporus agglutinin (ABA), Amaranthus Caudatus agglutinin (ACA), jacalin, Griffonia Simplicifolia lectin I (GSL-I) and Griffonia Simplicifolia lectin II (GSL-II). In one particular embodiment, the organ involved in respiration is chosen from the lungs, the larynx, the pharynx, the mouth, the nose, the throat, the tongue, the sinuses, the trachea and the saliva glands including the tonsils and the parotid gland.